Biomea Fusion Inc BMEA.OQ BMEA.O is expected to show no change in quarterly revenue when it reports results on April 1 (estimated) for the period ending December 31 2024
LSEG's mean analyst estimate for Biomea Fusion Inc is for a loss of 92 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Biomea Fusion Inc is $20.50, above its last closing price of $2.49.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -0.91 | -0.95 | -0.91 | Beat | 4.2 |
Jun. 30 2024 | -1.07 | -1.07 | -1.03 | Beat | 3.8 |
Mar. 31 2024 | -0.99 | -0.99 | -1.09 | Missed | -9.6 |
Dec. 31 2023 | -0.82 | -0.85 | -0.98 | Missed | -15.1 |
Sep. 30 2023 | -0.82 | -0.82 | -0.80 | Beat | 2.8 |
Jun. 30 2023 | -0.90 | -0.88 | -0.70 | Beat | 20 |
Mar. 31 2023 | -0.82 | -0.81 | -0.98 | Missed | -20.9 |
Dec. 31 2022 | -0.84 | -0.81 | -0.86 | Missed | -5.7 |
This summary was machine generated March 28 at 12:52 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。